A SARS-CoV-2 antigen rapid diagnostic test for resource limited settings.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
26 11 2021
Historique:
received: 30 06 2021
accepted: 10 11 2021
entrez: 27 11 2021
pubmed: 28 11 2021
medline: 15 12 2021
Statut: epublish

Résumé

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the causative agent of COVID-19 disease. RT-qPCR has been the primary method of diagnosis; however, the required infrastructure is lacking in many developing countries and the virus has remained a global challenge. More inexpensive and immediate test methods are required to facilitate local, regional, and national management strategies to re-open world economies. Here we have developed a SARS-CoV-2 antigen test in an inexpensive lateral flow format to generate a chromatographic result identifying the presence of the SARS-CoV-2 antigen, and thus an active infection, within a patient anterior nares swab sample. Our 15-min test requires no equipment or laboratory infrastructure to administer with a limit of detection of 2.0 × 10

Identifiants

pubmed: 34837001
doi: 10.1038/s41598-021-02128-y
pii: 10.1038/s41598-021-02128-y
pmc: PMC8626481
doi:

Substances chimiques

Antigens, Viral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

23009

Informations de copyright

© 2021. The Author(s).

Références

Lancet. 2021 Apr 17;397(10283):1425-1427
pubmed: 33609444
Diagnostics (Basel). 2021 Jun 30;11(7):
pubmed: 34208912
Lancet Microbe. 2021 Jan;2(1):e13-e22
pubmed: 33521734
BMJ. 2020 Dec 11;371:m4787
pubmed: 33310701
Clin Infect Dis. 2020 Dec 03;:
pubmed: 33270107
Lancet Infect Dis. 2021 Jul;21(7):e183-e190
pubmed: 33357517
J Med Virol. 2021 Apr;93(4):2177-2195
pubmed: 33095454
N Engl J Med. 2020 Nov 26;383(22):e120
pubmed: 32997903
J Clin Microbiol. 2021 Feb 18;59(3):
pubmed: 33310764

Auteurs

Erica Frew (E)

Bio-Techne, Devens, MA, USA. erica.frew@bio-techne.com.

Douglas Roberts (D)

Exosome Diagnostics, A Bio-Techne Brand, Waltham, MA, USA.

Shelly Barry (S)

Bio-Techne, Devens, MA, USA.

Matthew Holden (M)

Bio-Techne, Devens, MA, USA.

Amanda Restell Mand (A)

Bio-Techne, Devens, MA, USA.

Emily Mitsock (E)

Exosome Diagnostics, A Bio-Techne Brand, Waltham, MA, USA.

Enqing Tan (E)

Bio-Techne, Devens, MA, USA.

Wei Yu (W)

Exosome Diagnostics, A Bio-Techne Brand, Waltham, MA, USA.

Johan Skog (J)

Exosome Diagnostics, A Bio-Techne Brand, Waltham, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH